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The RNASEL gene (2′,5′-oligoisoadenylate-synthetase dependent) encodes a ribonuclease that mediates the antiviral
and apoptotic activities of interferons. The RNASEL gene maps to the hereditary-prostate-cancer (HPC)–predis-
position locus at 1q24-q25 (HPC1) and was recently shown to harbor truncating mutations in two families with
linkage to HPC1. Here, we screened for RNASEL germline mutations in 66 Finnish patients with HPC, and we
determined the frequency of the changes in the index patients from 116 families with HPC, in 492 patients with
unselected prostate cancer (PRCA), in 223 patients with benign prostatic hyperplasia (BPH), and in 566 controls.
A truncating mutation, E265X, was found in 5 (4.3%) of the 116 patients from families with HPC. This was
significantly higher (odds ratio ; ) than the frequency of E265X in controls (1.8%). The highest[OR]p 4.56 Pp .04
mutation frequency (9.5%) was found in patients from families with four or more affected members. Possible
segregation was detected only in a single family. However, the median age at disease onset for E265X carriers was
11 years less than that for noncarriers in the same families. In addition, of the four missense variants found, R462Q
showed an association with HPC ( ; ). None of the variants showed any differences betweenORp 1.96 Pp .07
controls and either patients with BPH or patients with PRCA. We conclude that, although RNASEL mutations do
not explain disease segregation in Finnish families with HPC, the variants are enriched in families with HPC that
include more than two affected members and may also be associated with the age at disease onset. This suggests
a possible modifying role in cancer predisposition. The impact that the RNASEL sequence variants have on PRCA
burden at the population level seems small but deserves further study.
Introduction
Prostate cancer (PRCA) is the most common cancer
among men in developed countries (Pentyala et al.
2000). A fraction of patients with PRCA belong to fam-
ilies with hereditary prostate cancer (HPC). Linkage
analyses in families with HPC have suggested that mul-
tiple genetic loci may harbor PRCA-susceptibility genes,
including HPC1 (MIM 601518), at 1q24-q25; ELAC2/
HPC2 (MIM 605367), at 17p11; PCAP (MIM 602759),
at 1q42.2-q43; HPCX (MIM 300147), at Xq27-q28;
CAPB (MIM 603688), at 1p36; and HPC20 (MIM
176807), at 20q13 (Ostrander and Stanford 2000). In
spite of the large number of loci reported, only the
ELAC2/HPC2 gene, at 17p11, has been implicated as
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a putative PRCA-susceptibility gene (Tavtigian et al.
2001). Although early studies (Rebbeck et al. 2000) sup-
ported the hypothesis that ELAC2/HPC2 mutations
played a role in PRCA, recent studies have found little
or no evidence that supports this hypothesis (Ro¨kman
et al. 2001; Suarez et al. 2001; Vesprini et al. 2001; Wang
et al. 2001; Xu et al. 2001).
The first PRCA-susceptibility locus—HPC1, at 1q24-
q25 (reported by Smith et al. [1996])—has been proven
to be significantly linked to disease in large families with
early-onset HPC (Xu 2000). The HPC1 region harbors
the 2′,5′-oligoisoadenylate (2-5A)–synthetase–dependent
gene RNASEL (MIM 180435), at 1q25 (Zhou et al.
1993), which is involved in the interferon-regulated 2-
5A system that mediates antiviral and antiproliferative
activities (Hassel et al. 1993; Castelli et al. 1998). RNA-
SEL was directly implicated as a candidate HPC1 gene
by the finding of disease-segregating mutations in high-
risk U.S. families with HPC (Carpten et al. 2002). A
truncating mutation (E265X) and an initiation-codon
mutation (M1I) segregated with disease in two families.
Furthermore, loss of the wild-type RNASEL allele was
found in tumor tissue from an affected patient in a family
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with the E265X mutation, accompanied by absent pro-
tein expression. Here, we investigated the significance of
RNASEL germline mutations in 116 Finnish families
with HPC, as well as in 492 patients with unselected
PRCA, 223 patients with benign prostatic hyperplasia
(BPH), and 566 controls.
Subjects and Methods
Families with HPC
Collection of Finnish families with HPC has been de-
scribed elsewhere (Schleutker et al. 2000). Samples from
the youngest affected patient available in each of 66
families with HPC were initially used for the screening
of mutations in the RNASEL gene, by SSCP analysis.
These families had either three or more affected members
or two affected members with at least the index patient
diagnosed with PRCA at !60 years of age. The mean
age at diagnosis for the index patients was 62.5 years
(range 44–76 years), and the mean number of affected
family members was 3.1 (range 2–6). Furthermore, sam-
ples from an additional set of 50 families with HPC
(from the youngest affected patient available in each
family) were also analyzed for specific mutations, bring-
ing the total number of samples from index patients with
HPC to 116. This second cohort of families had only
two affected members with ages at diagnosis 160 years.
The mean age at diagnosis for the index patients was
69.1 years (range 61–86). Specific mutations found in
the index patients were then assayed in all other avail-
able affected members of the 116 families ( ) andnp 65
in all available unaffected members of the five E265X-
mutation–positive families ( ). The PRCA diag-np 6
noses and the family histories of the patients were ini-
tially obtained from questionnaires and were subse-
quently confirmed by medical records, the Finnish Can-
cer Registry, and parish records.
Patients with PRCA, Patients with BPH, and Controls
We analyzed specific RNASEL mutations in 492 pa-
tients with unselected PRCA, in 223 patients with BPH,
and in 566 healthy male blood donors. The patients with
PRCA and the patients with BPH were consecutive pa-
tients diagnosed in the Tampere University Hospital in
Finland during 1996–99, whereas the controls consisted
of DNA samples from blood donors obtained from the
Blood Center of the Finnish Red Cross in Tampere. Tam-
pere University Hospital is a regional referral center for
all patients in the area who have PRCA, which results
in an unselected, population-based collection of patients.
The mean age at diagnosis for the patients with unse-
lected PRCA was 68.3 years (range 52–88). Information
was available on the tumor grade in 94% (461/492) of
patients, on T-stage in 93% (460/492) of patients, and
on M-stage (ascertained by bone scan) in 94% (462/
492) of patients. Forty-seven (9.6%) of the patients with
unselected PRCA reported a positive family history of
PRCA. Diagnosis of BPH was based on lower-urinary-
tract symptoms, free uroflowmetry, and evidence, by pal-
pation or transrectal ultrasound, of increased prostate
size. If prostate-specific antigen (PSA) was elevated, then
the patients underwent prostate biopsies to exclude
PRCA. Indication for prostate biopsy was total PSA of
4 ng/ml or total PSA of 3.0–3.9 ng/ml with free PSA
!16%. Most patients with BPH were followed up for
3–5 years and did not develop PRCA during that time.
Written informed consent was obtained from all living
patients and also, for families with HPC, from the un-
affected members. The research protocols were ap-
proved by the Ethical Committee of the Tampere Uni-
versity Hospital (93175, 95062, and 99228) and the
National Human Genome Research Institute (HG-
0158). Permission for collection of families in the en-
tirety of Finland was granted by the Ministry of Health
and Social Affairs (59/08/95).
Mutation Screening with SSCP Analysis
SSCP analysis of the entire coding sequence of the
RNASEL gene was performed using primer sequences
that were designed to include all intron-exon boundaries
(according to Carpten et al. [2002]). On request, all prim-
ers are available from the authors. Genomic DNA was
used at 100 ng/15 ml reaction mixture (containing 1.5
mM MgCl2; 20 mM each of dATP, dCTP, dGTP, and
dTTP; 0.5 mCi of a[33P]-dCTP [Amersham Pharmacia];
0.6 mM of each primer; 1.5 U AmpliTaqGold; and the
reaction buffer provided by the supplier [PE Biosystems]),
with an annealing temperature of 56C. Radiolabeled
PCR products were mixed with 95% formamide dye,
were denatured at 95C for 5 min, and were chilled on
ice. The [33P]-labeled PCR products were electrophoresed
at 800 V for 13 h at room temperature, in 0.5# (with
and without 1% glycerol) and 0.8# MDE (mutation-
detection–enhancement) gel (FMC BioProducts) in 0.5#
Tris-borate EDTA. After electrophoresis, gels were dried
and were exposed to Kodak BioMax MR (maximum-
resolution) films for 4 h. All samples in which variant
bands were detected, as well as two to three normal bands
per exon, were analyzed by sequencing, by use of the same
PCR primers. Also, the genotypes of the available family
members of the carriers were determined by sequencing,
which was performed using an automated ABI Prism 310
Genetic Analyzer (PE Biosystems) according to the in-
structions of the manufacturer.
Mutation Screening with Conformation-Sensitive Gel
Electrophoresis (CSGE) Analysis
CSGE analysis (Ganguly et al. 1993) of the coding
region of the RNASEL gene was performed using the
same primer sequences as in SSCP analysis. 5′-Labeling
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Table 1
Summary of RNASEL Sequence Variants Found in 66
Patients with HPC in the SSCP Analysis
Exon Codon
Positiona; Nucleotide Change (Codon/
Amino Acid Change)
2 59b 175; GrA (GGCrAGC/GlyrSer)
2 265b 793; GrT (GAGrTAG/GlurStop)
2 393 1179; GrA
2 406 1217; CrT (TCTrTTT/SerrPhe)
2 462b 1385; GrA (CGArCAA/ArgrGln)
4 541b 1623; TrG (GATrGAG/AsprGlu)
7 724 2172; GrA
a Numbering is according to the cDNA starting at the
A in the start codon.
b Also reported by Carpten et al. (2002).
reaction was performed in a 30-ml volume (containing
45 pmol of the forward primer, 45 mCi of g[33P]-ATP
[Amersham Pharmacia], and 15 U T4 polynucleotide
kinase [New England Biolabs]) in 37C for 60 min. The
PCR contained 2.25 mM MgCl2, 200 mM each dNTP,
5.4 pmol of the unlabeled forward primer, 0.6 pmol of
the labeled forward primer, 6 pmol of the reverse primer,
and 1.25 U of AmpliTaqGold. The amplification con-
ditions were the same as those in the SSCP analysis. The
PCR was heated to 95C for 10 min in a PCR machine,
and, then, the machine was switched off to allow the
products to slowly form heteroduplexes as they cooled
to room temperature. Five microliters of the sample was
mixed with 7.5 ml of 30% glycerol containing 0.25%
each of xylene cyanol and bromophenol blue. The la-
beled PCR products were electrophoresed overnight at
5 W (for two gels) in the gel prepared with 10% poly-
acrylamide (75:1 ratio of acrylamide:bisacrylamide),
10% ethylene glycol, and 15% formamide, in 0.5#TTE
buffer (1# TTE is 89 mM Tris, 29 mM taurine buffer,
and 0.5 mM EDTA, with pH 9). All samples in which
variant bands were detected, as well as two to three
normal bands per exon, were analyzed by sequencing,
by use of the same PCR primers.
Minisequencing for Large-Scale Population Screening
of Identified Variants
The frequencies of the RNASEL variants at the pop-
ulation level were determined by minisequencing (Sy-
va¨nen 1998). The most interesting variant, E265X, and
the G59S variant were screened in the entire sample of
patients described above. S406F, R462Q, and D541E
missense variants were screened in 176 controls and 167
patients with unselected PRCA. PCR was performed
with 100 ng of DNA, 0.2 mM each primer, 0.2 mM each
dNTP, 1.5 mM MgCl2, and 1.0 U of AmpliTaqGold (PE
Biosystems), in a final volume of 50 ml. Positive results
were confirmed by the sequencing, by use of the PCR
primers, of two or three positive results from each min-
isequencing reaction.
Statistical Analyses
Association of the RNASEL genotypes with HPC,
PRCA, and BPH was tested by logistic-regressionanalysis,
by use of the SPSS statistical software package (SPSS
1999). Association with demographic, clinical, and path-
ological features of the disease was tested by the Mann-
Whitney test, by use of the SPSS statistical software pack-
age and Fisher’s exact test with StatXact (Cytel Software
1999; SPSS 1999).
Results
Seven sequence variants were found in the SSCP analysis
of the RNASEL gene in 66 index patients from Finnish
families with HPC (table 1). These variants included a
truncating mutation, E265X, which has also been re-
ported by Carpten et al. (2002). No additional variants
were found in the CSGE analysis. E265X was then tested
in another, independent set of 50 small families with
HPC, bringing the total number of index patients with
HPC to 116. The overall E265X-mutation frequency in
patients with HPC was 4.3% (table 2). This was sig-
nificantly higher (odds ratio ; 95% CI[OR]p 4.56
1.1–19.4; table 3) than the frequency (1.8%) seen in the
population sample of 566 blood donors. When stratified
by family size, index patients from families with three
affected members ( ; 95% CI 1.1–43.5) andORp 7.00
from those with four or more affected members
( ; 95% CI 1.7–67.7) had significantly ele-ORp 10.67
vated E265X-mutation frequencies. Two (9.5%) of 21
patients from families with HPC with four or more af-
fected members were E265X positive. In contrast, in
patients from families with HPC with only two affected
members, the mutation frequency, 1.6%, was not sig-
nificantly different from that seen in controls (ORp
; 95% CI 0.2–15.7).1.61
We then tested additional samples from the other af-
fected members of the 116 families with HPC, as well
as all available samples from unaffected members of the
E265X-mutation–positive families, for the E265X mu-
tation. Suggestive evidence of segregation between the
E265X mutation and PRCA was seen only in a single
family with three affected members. In this family, two
affected brothers were mutation carriers, whereas their
unaffected, 50-year-old brother did not carry the mu-
tation (fig. 1). No sample was available from their af-
fected father. Of the remaining four E265X-positive
families with HPC, two had samples available only from
a single affected sib pair, one had samples available from
three affected members, and one had samples available
from four affected members. However, in each of these
families, only one affected person carried the E265X
mutation. None of the unaffected family members tested
were mutation positive. In the five families in which the
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Table 2
Genotype Frequencies of RNASEL Sequence Variants in Controls, Patients with
Unselected PRCA, and Patients with HPC
VARIANT
AND GENOTYPE
NO./TOTAL (FREQUENCY) IN
Controls
Patients with
PRCA HPC
E265Xa:
G 556/566 (98.2%) 482/492 (98.0%) 111/116 (95.7%)
GT 10/566 (1.8%) 10/492 (2.0%) 5/116 (4.3%)
S406F:
C 173/176 (98.3%) 160/167 (95.8%) 63/66 (95.5%)
CT 3/176 (1.7%) 7/167 (4.2%) 3/66 (4.5%)
R462Q:
G 69/176 (39.2%) 60/167 (35.9%) 28/66 (42.4%)
GA 84/176 (47.7%) 83/167 (49.7%) 23/66 (34.8%)
A 23/176 (13.1%) 24/167 (14.4%) 15/66 (22.7%)
D541E:
T 29/176 (16.5%) 21/167 (12.6%) 8/66 (12.1%)
TG 91/176 (51.7%) 94/167 (56.3%) 32/66 (48.5%)
G 56/176 (31.8%) 52/167 (31.1%) 26/66 (39.4%)
a Because of the complete linkage disequilibrium, frequencies for G59S are the
same as those for E265X.
E265X mutation was found, the median age at diag-
nosis for the six mutation carriers was 11 years younger
than that for the seven affected members who were not
carriers ( ; Mann-Whitney test).Pp .07
The frequencies of the E265X (table 2) and G59S
variants were then compared, at the population level,
in families with HPC ( ), in controls ( ),np 116 np 566
in patients with unselected PRCA ( ), and innp 492
patients with BPH ( ). All E265X carriers foundnp 223
were heterozygotes. E265X was found to be in complete
linkage disequilibrium with G59S, but neither variant
showed a significant association with either PRCA or
BPH. S406F, R462Q, and D541E missense variants
were analyzed in the index patients from 66 families
with HPC, 176 controls, and 167 patients with PRCA
(table 2). All gene frequencies were found to be in
Hardy-Weinberg equilibrium. R462Q homozygotes
were found to be more common among patients with
HPC (22.7%) than among the controls (13.1%), indi-
cating a possible association with HPC risk (ORp
; 95% CI 0.9–4.0; ; table 3). The frequency1.96 Pp .07
was highest (28.6%) in families with four or more af-
fected members. The other missense variants did not
show any significant associations with either HPC or
PRCA. We also analyzed the association between these
variants and disease phenotype, including T-stage, M-
stage, and tumor grade, among patients with unselected
PRCA (Fisher’s exact test). No significant associations
emerged from these analyses (data not shown).
Discussion
RNASEL was recently suggested as a candidate HPC1
gene, on the basis of the finding that a truncating mu-
tation (E265X) and an initiation-codon mutation (M1I)
segregate in two families with HPC with linkage to
HPC1 (Carpten et al. 2002). The E265X variant has
been proven to cause a dramatic decrease in the enzy-
matic activity of RNASEL (Dong and Silverman 1999).
Loss of the wild-type allele and loss of the protein ex-
pression in tumor tissues from a patient in an E265X-
mutation–positive family with linkage to HPC1 were
also reported (Carpten et al. 2002).
Our most significant finding—which suggests that the
RNASEL gene is involved in PRCA predisposition—
came from the higher frequency of the E265X truncat-
ing mutation in patients from Finnish families with
HPC, as compared to its frequency in controls. An OR
of 4.56 was obtained for E265X when all patients with
familial disease were considered, and an OR of 10.67
was obtained when families with HPC with four or
more affected members were considered.
We found that the prevalence (5/116 [4.3%]) of
E265X mutations in the Finnish index patients with
HPC was somewhat higher than that which had been
found in the U.S. study reported by Carpten et al.
(2002), in which the E265X mutation was found in only
1 (3.8%) of the 26 patients with HPC whom they stud-
ied. This is despite the fact that Carpten et al. (2002)
specifically studied families with linkage to HPC1,
whereas the families that we studied were not selected
on the basis of prior linkage results. In fact, families
with linkage to HPC1 are rare in Finland (Schleutker
et al. 2000), and, of the seven candidate families with
HPC1 linkage (defined as LOD score 10.25) that have
been studied here, none carried E265X mutations of the
RNASEL gene.
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Figure 1 Pedigree structure of an E265X-positive family with
HPC. E265X-mutation carriers are denoted by a plus sign (), and
noncarriers are denoted by a minus sign (). Age or age at diagnosis
(dg) (in years) is indicated below the symbol for each family member.
Table 3
Association of the Truncating Mutation E265X and Missense Variant R462Q of the RNASEL
Gene with Patients with BPH, Unselected PRCA, or HPC
Patient or Family Sample
and Mutation
No. of Carriers/
Total (Frequency) OR 95% CI P
E265X:
Controls 10/566 (1.8%) 1.00 … …
Patients with BPH 7/223 (3.1%) 1.80 .68–4.79 .75
Patients with unselected PRCA 10/492 (2.0%) 1.15 .48–2.80 .24
All patients with HPC 5/116 (4.3%) 4.56 1.07–19.42 .04a
Two affecteds 1/64 (1.6%) 1.61 .17–15.71 .68
Three affecteds 2/31 (6.5%) 7.00 1.12–43.53 .04a
Four or more affecteds 2/21 (9.5%) 10.67 1.68–67.72 .01a
R462Q homozygotes:
Controls 23/176 (13.1%) 1.00 … …
Patients with unselected PRCA 24/167 (14.4%) 1.12 .60–2.07 .73
All patients with HPC 15/66 (22.7%) 1.96 .95–4.03 .07
Two affecteds 2/19 (10.5%) 0.78 .17–3.61 .75
Three affecteds 7/26 (26.9%) 2.45 .93–6.47 .07
Four or more affecteds 6/21 (28.6%) 2.66 .94–7.55 .07
a Statistically significant.
Consistent with this view, possible evidence of segre-
gation of the E265X mutation was seen only in a single
Finnish family, in which two affected brothers were car-
riers and in which an unaffected brother was a noncarrier.
Their father was also diagnosed with PRCA, but he was
unavailable for study (fig. 1). In four other E265X-pos-
itive families, no segregation was found. In the E265X-
positive families, the diagnosis of PRCA was based on
symptomatic disease, not on PSA testing. Similarly, Carp-
ten et al. (2002) reported segregation of the E265X mu-
tation with disease in a single family. Therefore, our re-
sults indicate a significant disease association when
E265X-mutation frequencies are compared between in-
dex patients with HPC and controls, but they indicate a
lack of evidence of segregation with disease in these fam-
ilies. This observation could be explained by the fact that
the HPC1 mutations are not sufficient to cause disease
but perhaps act as modifiers of disease onset. In support
of this hypothesis, we found that, in all families with
E265X mutations, there was a tendency for PRCA to be
diagnosed ∼11 years earlier in mutation carriers than in
noncarriers ( ).Pp .07
Besides E265X, we found four missense variants—
G59S, S406F, R462Q, and D541E—and two silent base
substitutions. Of these, S406F was not reported in the
study by Carpten et al. (2002). R462Q and D541E are
also found in an SNP database maintained by the Na-
tional Center for Biotechnology Information (see the
dbSNP Home Page). To evaluate the impact that the
RNASELmissense variants have at the population level,
we determined their frequencies in patients with HPC,
in patients with unselected PRCA, and in a group of
male blood donors. G59S frequencies were significantly
different in the patients with HPC than in the controls,
because of the complete linkage disequilibrium with
E265X. Also, R462Q homozygotes were more common
in families with HPC than in the controls. Therefore,
two RNASEL variants showed an association with
HPC, but no effect that the RNASEL variants had at
the population level could be distinguished.
In conclusion, our results suggest that the E265X and
R462Q variants of the RNASEL gene may influence
disease onset in large families with HPC. The variants
are most often seen in patients from families with HPC
with three or more affected members. However, neither
variant alone seems to explain the familial clustering of
prostate cancer. Furthermore, in the analysis of 11,300
individuals, we were not able to demonstrate a signif-
icant impact that any of the RNASEL variants had in
the causation of PRCA at the population level. The pres-
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ent results warrant further studies of the role that RNA-
SEL variants have as risk factors for HPC and unse-
lected PRCA in other populations.
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